Skip to main content
Top
Published in: Dermatology and Therapy 2/2019

Open Access 01-06-2019 | Itraconazole | Review

Itraconazole in the Treatment of Nonfungal Cutaneous Diseases: A Review

Authors: Ya-Chu Tsai, Tsen-Fang Tsai

Published in: Dermatology and Therapy | Issue 2/2019

Login to get access

Abstract

Introduction

The anti-inflammatory and pro-kinetic properties of antibiotics have been widely reported. However, the non-antifungal properties of antifungal agents are less well known and less explored in clinical practice. The purpose of this review was to survey the literature on the non-antifungal use of itraconazole in dermatological practice and the possible modes of action of this agent.

Methods

The PubMed database was searched for relevant articles published up to January 2017. The references in the articles identified by the search were then hand-searched for additional relevant publications.

Results

Itraconazole displays a great diversity of non-antifungal activity and has been used to treat a broad spectrum of diseases. The results of our survey reveal that itraconazole has the potential to be an alternative agent for treating patients with advanced cancer (either alone or in combination with other cytotoxic chemotherapeutic drugs), especially those refractory to traditional treatments. Moreover, itraconazole acts as an anti-angiogenesis agent, induces nail growth, and modulates inflammatory or immune diseases.

Conclusion

Oral antifungal agents have many non-antifungal properties. However, the body of evidence on individual agents often remains limited due to the lack of large-scale randomized controlled studies. Although some of the findings published to date seem promising, pharmacological vigilance should be taken for off-label use in real-world practice.
Literature
1.
go back to reference Tsai TF, Yeh TY. Allopurinol in dermatology. Am J Clin Dermatol. 2010;11:225–32.CrossRef Tsai TF, Yeh TY. Allopurinol in dermatology. Am J Clin Dermatol. 2010;11:225–32.CrossRef
2.
go back to reference Huang J, Su W, Chen X, et al. Doxycycline attenuates endotoxin-induced uveitis by prostaglandin E2-EP4 signaling. Investig Ophthalmol Vis Sci. 2015;56:6686–93.CrossRef Huang J, Su W, Chen X, et al. Doxycycline attenuates endotoxin-induced uveitis by prostaglandin E2-EP4 signaling. Investig Ophthalmol Vis Sci. 2015;56:6686–93.CrossRef
3.
go back to reference Budni J, Garcez ML, de Medeiros J, et al. The anti-inflammatory role of minocycline in Alzheimer´s disease. Curr Alzheimer Res. 2016;13:1319–29.CrossRef Budni J, Garcez ML, de Medeiros J, et al. The anti-inflammatory role of minocycline in Alzheimer´s disease. Curr Alzheimer Res. 2016;13:1319–29.CrossRef
4.
go back to reference Yi C, Zhang Z, Wang W, et al. Doxycycline attenuates peripheral inflammation in rat experimental autoimmune neuritis. Neurochem Res. 2011;36:1984–90.CrossRef Yi C, Zhang Z, Wang W, et al. Doxycycline attenuates peripheral inflammation in rat experimental autoimmune neuritis. Neurochem Res. 2011;36:1984–90.CrossRef
5.
go back to reference Kim J, Tang JY, Gong R, et al. Itraconazole, a commonly used antifungal that inhibits Hedgehog pathway activity and cancer growth. Cancer Cell. 2010;17:388–99.CrossRef Kim J, Tang JY, Gong R, et al. Itraconazole, a commonly used antifungal that inhibits Hedgehog pathway activity and cancer growth. Cancer Cell. 2010;17:388–99.CrossRef
6.
go back to reference Kim J, Aftab BT, Tang JY, et al. Itraconazole and arsenic trioxide inhibit Hedgehog pathway activation and tumor growth associated with acquired resistance to smoothened antagonists. Cancer Cell. 2013;23:23–34.CrossRef Kim J, Aftab BT, Tang JY, et al. Itraconazole and arsenic trioxide inhibit Hedgehog pathway activation and tumor growth associated with acquired resistance to smoothened antagonists. Cancer Cell. 2013;23:23–34.CrossRef
8.
go back to reference Kim DJ, Kim J, Spaunhurst K, et al. Open-label, exploratory phase II trial of oral itraconazole for the treatment of basal cell carcinoma. J Clin Oncol. 2014;32:745–51.CrossRef Kim DJ, Kim J, Spaunhurst K, et al. Open-label, exploratory phase II trial of oral itraconazole for the treatment of basal cell carcinoma. J Clin Oncol. 2014;32:745–51.CrossRef
9.
go back to reference Aftab BT, Dobromilskaya I, Liu JO, et al. Itraconazole inhibits angiogenesis and tumor growth in non-small cell lung cancer. Cancer Res. 2011;71:6764–72.CrossRef Aftab BT, Dobromilskaya I, Liu JO, et al. Itraconazole inhibits angiogenesis and tumor growth in non-small cell lung cancer. Cancer Res. 2011;71:6764–72.CrossRef
10.
go back to reference Nacev BA, Grassi P, Dell A, et al. The antifungal drug itraconazole inhibits vascular endothelial growth factor receptor 2 (VEGFR2) glycosylation, trafficking, and signaling in endothelial cells. J Biol Chem. 2011;286:44045–56.CrossRef Nacev BA, Grassi P, Dell A, et al. The antifungal drug itraconazole inhibits vascular endothelial growth factor receptor 2 (VEGFR2) glycosylation, trafficking, and signaling in endothelial cells. J Biol Chem. 2011;286:44045–56.CrossRef
11.
go back to reference Ran Y, Chen S, Dai Y, et al. Successful treatment of oral itraconazole for infantile hemangiomas: a case series. J Dermatol. 2015;42:202–6.CrossRef Ran Y, Chen S, Dai Y, et al. Successful treatment of oral itraconazole for infantile hemangiomas: a case series. J Dermatol. 2015;42:202–6.CrossRef
12.
go back to reference Okada E, Maruyama Y. Are keloids and hypertrophic scars caused by fungal infection? Plast Reconstr Surg. 2007;120:814–5.CrossRef Okada E, Maruyama Y. Are keloids and hypertrophic scars caused by fungal infection? Plast Reconstr Surg. 2007;120:814–5.CrossRef
13.
go back to reference Chui CH. Treatment of keloids with itraconazole. Plast Reconstr Surg. 2008;122:681–2.CrossRef Chui CH. Treatment of keloids with itraconazole. Plast Reconstr Surg. 2008;122:681–2.CrossRef
14.
go back to reference Mihara M, Hagari Y, Morimura T, et al. Itraconazole as a new treatment for pustulosis palmaris et plantaris. Arch Dermatol. 1998;134:639–40.CrossRef Mihara M, Hagari Y, Morimura T, et al. Itraconazole as a new treatment for pustulosis palmaris et plantaris. Arch Dermatol. 1998;134:639–40.CrossRef
15.
go back to reference V’lckova-Laskoska MT, Caca-Biljanovska NG, Laskoski DS, et al. Palmoplantar pustulosis treated with itraconazole: a single, active-arm pilot study. Dermatol Ther. 2009;22:85–9.CrossRef V’lckova-Laskoska MT, Caca-Biljanovska NG, Laskoski DS, et al. Palmoplantar pustulosis treated with itraconazole: a single, active-arm pilot study. Dermatol Ther. 2009;22:85–9.CrossRef
16.
go back to reference Berger TG, Heon V, King C, Schulze K, et al. Itraconazole therapy for human immunodeficiency virus-associated eosinophilic folliculitis. Arch Dermatol. 1995;131:358–60.CrossRef Berger TG, Heon V, King C, Schulze K, et al. Itraconazole therapy for human immunodeficiency virus-associated eosinophilic folliculitis. Arch Dermatol. 1995;131:358–60.CrossRef
17.
go back to reference Libow LF, Coots NV. Treatment of lichen planus and lichen nitidus with itraconazole: reports of six cases. Cutis. 1998;62:247–8.PubMed Libow LF, Coots NV. Treatment of lichen planus and lichen nitidus with itraconazole: reports of six cases. Cutis. 1998;62:247–8.PubMed
18.
go back to reference Khandpur S, Sugandhan S, Sharma VK. Pulsed itraconazole therapy in eruptive lichen planus. J Eur Acad Dermatol Venereol. 2009;23:98–101.CrossRef Khandpur S, Sugandhan S, Sharma VK. Pulsed itraconazole therapy in eruptive lichen planus. J Eur Acad Dermatol Venereol. 2009;23:98–101.CrossRef
19.
go back to reference Tercelj M, Rott T, Rylander R. Antifungal treatment in sarcoidosis–a pilot intervention trial. Respir Med. 2007;101:774–8.CrossRef Tercelj M, Rott T, Rylander R. Antifungal treatment in sarcoidosis–a pilot intervention trial. Respir Med. 2007;101:774–8.CrossRef
20.
go back to reference Cooper SM, Sheridan A, Burge S. Mycosis fungoides responding to systemic itraconazole. J Eur Acad Dermatol Venereol. 2003;17:588–90.CrossRef Cooper SM, Sheridan A, Burge S. Mycosis fungoides responding to systemic itraconazole. J Eur Acad Dermatol Venereol. 2003;17:588–90.CrossRef
21.
go back to reference Pawelec G, Ehninger G, Rehbein A, et al. Comparison of the immunosuppressive activities of the antimycotic agents itraconazole, fluconazole, ketoconazole and miconazole on human T-cells. Int J Immunopharmacol. 1991;13:299–304.CrossRef Pawelec G, Ehninger G, Rehbein A, et al. Comparison of the immunosuppressive activities of the antimycotic agents itraconazole, fluconazole, ketoconazole and miconazole on human T-cells. Int J Immunopharmacol. 1991;13:299–304.CrossRef
22.
go back to reference Rosen T, Schell BJ, Orengo I. Anti-inflammatory activity of antifungal preparations. Int J Dermatol. 1997;36:788–92.CrossRef Rosen T, Schell BJ, Orengo I. Anti-inflammatory activity of antifungal preparations. Int J Dermatol. 1997;36:788–92.CrossRef
23.
go back to reference Vuddhakul V, Mai GT, McCormack JG, et al. Suppression of neutrophil and lymphoproliferative responses in vitro by itraconazole but not fluconazole. Int J Immunopharmacol. 1990;12:639–45.CrossRef Vuddhakul V, Mai GT, McCormack JG, et al. Suppression of neutrophil and lymphoproliferative responses in vitro by itraconazole but not fluconazole. Int J Immunopharmacol. 1990;12:639–45.CrossRef
24.
go back to reference Steel HC, Tintinger GR, Anderson R. Comparison of the anti-inflammatory activities of imidazole antimycotics in relation to molecular structure. Chem Biol Drug. 2008;72:225–8.CrossRef Steel HC, Tintinger GR, Anderson R. Comparison of the anti-inflammatory activities of imidazole antimycotics in relation to molecular structure. Chem Biol Drug. 2008;72:225–8.CrossRef
25.
go back to reference Luyten C, André J, Walraevens C, et al. Yellow nail syndrome and onychomycosis. Experience with itraconazole pulse therapy combined with vitamin E. Dermatology. 1996;192:406–8.CrossRef Luyten C, André J, Walraevens C, et al. Yellow nail syndrome and onychomycosis. Experience with itraconazole pulse therapy combined with vitamin E. Dermatology. 1996;192:406–8.CrossRef
26.
go back to reference De Donker P, Pierard GE. Acquired nail beading in patients receiving itraconazole—an indicator of faster nail growth? A study using optical profilometry. Clin Exp Dermatol. 1994;19:404–6.CrossRef De Donker P, Pierard GE. Acquired nail beading in patients receiving itraconazole—an indicator of faster nail growth? A study using optical profilometry. Clin Exp Dermatol. 1994;19:404–6.CrossRef
27.
go back to reference Tosti A, Piraccini BM, Iorizzo M. Systemic itraconazole in the yellow nail syndrome. Br J Dermatol. 2002;146:1064–7.CrossRef Tosti A, Piraccini BM, Iorizzo M. Systemic itraconazole in the yellow nail syndrome. Br J Dermatol. 2002;146:1064–7.CrossRef
28.
go back to reference Kaffenberger BH, Mathis J, Zirwas MJ. A retrospective descriptive study of oral azole antifungal agents in patients with patch test-negative head and neck predominant atopic dermatitis. J Am Acad Dermatol. 2014;71:480–3.CrossRef Kaffenberger BH, Mathis J, Zirwas MJ. A retrospective descriptive study of oral azole antifungal agents in patients with patch test-negative head and neck predominant atopic dermatitis. J Am Acad Dermatol. 2014;71:480–3.CrossRef
29.
go back to reference El Svejgaard, Larsen PØ, Deleuran M, et al. Treatment of head and neck dermatitis comparing itraconazole 200 mg and 400 mg daily for 1 week with placebo. J Eur Acad Dermatol Venereol. 2004;18:445–9.CrossRef El Svejgaard, Larsen PØ, Deleuran M, et al. Treatment of head and neck dermatitis comparing itraconazole 200 mg and 400 mg daily for 1 week with placebo. J Eur Acad Dermatol Venereol. 2004;18:445–9.CrossRef
30.
go back to reference Ikezawa Z, Kondo M, Okajima M, et al. Clinical usefulness of oral itraconazole, an antimycotic drug, for refractory atopic dermatitis. Eur J Dermatol. 2004;14:400–6.PubMed Ikezawa Z, Kondo M, Okajima M, et al. Clinical usefulness of oral itraconazole, an antimycotic drug, for refractory atopic dermatitis. Eur J Dermatol. 2004;14:400–6.PubMed
32.
go back to reference Faergemann J, Diehl U, Bergfelt L, et al. Scalp psoriasis: synergy between the Malassezia yeasts and skin irritation due to calcipotriol. Acta Derm Venereol. 2003;83:438–41.CrossRef Faergemann J, Diehl U, Bergfelt L, et al. Scalp psoriasis: synergy between the Malassezia yeasts and skin irritation due to calcipotriol. Acta Derm Venereol. 2003;83:438–41.CrossRef
Metadata
Title
Itraconazole in the Treatment of Nonfungal Cutaneous Diseases: A Review
Authors
Ya-Chu Tsai
Tsen-Fang Tsai
Publication date
01-06-2019
Publisher
Springer Healthcare
Published in
Dermatology and Therapy / Issue 2/2019
Print ISSN: 2193-8210
Electronic ISSN: 2190-9172
DOI
https://doi.org/10.1007/s13555-019-0299-9

Other articles of this Issue 2/2019

Dermatology and Therapy 2/2019 Go to the issue
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.